Company: CMND
Filing Date: 2025-03-13
Form Type: POS AM
Source: 0001213900-25-023708
Chunk: 11

Company: Clearmind Medicine Inc.
Filing Date: 2025-03-13
Form: POS AM
Chunk 11
---
 of the securities that are
held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter, or
(c) the date on which we have issued more than $1 billion in nonconvertible debt during the preceding three-year period.

Foreign Private Issuer

We are subject to the information reporting requirements
of the Exchange Act that are applicable to “foreign private issuers,” and under those requirements we will file reports with
the United States Securities and Exchange Commission, or SEC. As a foreign private issuer, we are not subject to the same requirements
that are imposed upon U.S. domestic issuers by the SEC. Under the Exchange Act, we are subject to reporting obligations that, in certain
respects, are less detailed and less frequent than those of U.S. domestic reporting companies. For example, although we report our financial
results on a quarterly basis, we will not be required to issue quarterly reports, proxy statements that comply with the requirements
applicable to U.S. domestic reporting companies, or individual executive compensation information that is as detailed as that required
of U.S. domestic reporting companies. We also have four months after the end of each fiscal year to file our annual reports with the
SEC and are not required to file current reports as frequently or promptly as U.S. domestic reporting companies. We also present financial
statements pursuant to IFRS instead of pursuant to U.S. generally accepted accounting principles. Furthermore, although the members of
our management and supervisory boards will be required to notify the Israeli Securities Authority, of certain transactions they may undertake,
including with respect to our Common Shares, our officers, directors and principal shareholders will be exempt from the requirements
to report transactions in our equity securities and from the short-swing profit liability provisions contained in Section 16 of the Exchange
Act. As a foreign private issuer, we are also not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the
Exchange Act. In addition, as a foreign private issuer, we are permitted, and follow certain home country corporate governance practices
instead of those otherwise required under the listing rules of Nasdaq for domestic U.S. issuers. These exemptions and leniencies reduce
the frequency and scope of information and protections available to you in comparison to those applicable to a U.S. domestic reporting
companies.

We may take advantage of these exemptions until
such time as we are no longer a foreign private issuer. We would cease to be a